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Background and Purpose: The phosphatidylinositol-3-kinase (PI3K)/Akt pathway is frequently deregulated in
prostate cancer and associated with neoplastic transformation, malignant progression, and enhanced resistance to
classical chemotherapy and radiotherapy. Thus, it is a promising target for therapeutic intervention. In the present
study, the cytotoxic action of the Akt inhibitor Erufosine (ErPC3) was analyzed in prostate cancer cells and
compared to the cytotoxicity of the PI3K inhibitor LY294002. Moreover, the efficacy of combined treatment with
Akt inhibitors and ionizing radiation in prostate cancer cells was examined.
Materials and methods: Prostate cancer cell lines PC3, DU145, and LNCaP were treated with ErPC3 (1-100 µM),
LY294002 (25-100 µM), irradiated (0-10 Gy), or subjected to combined treatments. Cell viability was determined by
the WST-1 assay. Apoptosis induction was analyzed by flow cytometry after staining with propidium iodide in a
hypotonic citrate buffer, and by Western blotting using antibodies against caspase-3 and its substrate PARP. Akt
activity and regulation of the expression of Bcl-2 family members and key downstream effectors involved in
apoptosis regulation were examined by Western blot analysis.
Results: The Akt inhibitor ErPC3 exerted anti-neoplastic effects in prostate cancer cells, however with different
potency. The anti-neoplastic action of ErPC3 was associated with reduced phosphoserine 473-Akt levels and
induction of apoptosis. PC3 and LNCaP prostate cancer cells were also sensitive to treatment with the PI3K
inhibitor LY294002. However, the ErPC3-sensitive PC3-cells were less susceptible to LY294002 than the ErPC3-
refractory LNCaP cells. Although both cell lines were largely resistant to radiation-induced apoptosis, both cell lines
showed higher levels of apoptotic cell death when ErPC3 was combined with radiotherapy.
Conclusions: Our data suggest that constitutive Akt activation and survival are controlled by different different
molecular mechanisms in the two prostate cancer cell lines - one which is sensitive to the Akt-inhibitor ErPC3 and
one which is more sensitive to the PI3K-inhibitor LY294002. Our findings underline the importance for the
definition of predictive biomarkers that allow the selection patients that may benefit from the treatment with a
specific signal transduction modifier.
Introduction
Prostate cancer is the most commonly diagnosed malig-
nancy in men. Radical prostatectomy, hormone ablation
therapy, and radiotherapy are available for treatment of
localized stages yielding >50% of local control [1,2].
Radiotherapy is also an integral part of treatment proto-
cols for inoperable locally advanced prostate cancer.
Despite the use of classical chemotherapy (mainly tax-
anes), hormone ablation therapy, radiopharmaceuticals,
and refined radiation methods, no curative treatment for
advanced stages is available to date. Thus, novel
approaches are needed particularly for the treatment of
patients with hormone-refractory disease [3,4].
Malignant progression is mostly associated with
resistance to cell death induction by chemo- and radio-
therapy. Therefore, molecular targeting agents that over-
come cell death resistance or increase the sensitivity of
malignant cells to the cytotoxic action of chemo- or
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outcome in localized disease and advanced stages.
Altered signaling pathways within the tumor cells that
affect tumor cell survival are in focus for the develop-
ment of innovative anticancer drugs. The PI3K/Akt
pathway is one of the most important survival signaling
cascades altered in human solid tumors including pros-
tate cancer [5,6]. In normal cells, this pathway transmits
growth and survival signals from cell surface receptors
to promote cell survival in response to cellular stress.
An aberrant activation of growth factor receptors, acti-
vating mutations of PI3K, or the inactivation of the
tumor suppressor phosphatase and tensin homolog on
chromosome ten (PTEN) which counteracts PI3K lead
to an constitutive activation of the PI3K/Akt pathway.
Up-regulated activity of the kinase Akt is associated
with malignant transformation characterized by acceler-
ated tumor growth, metastasis, and angiogenesis. More-
over, activated Akt decreases sensitivity of tumor cells
to chemotherapy and radiotherapy by increasing the
threshold for cell death induction [7]. Therefore,
the survival kinase Akt attracted major attention for the
development of molecularly targeted approaches for the
treatment of human solid tumors including prostate
cancer and overcoming resistance to standard genotoxic
chemo- and radiotherapy. Importantly, Akt is embedded
into a highly complex network of upstream regulators
and downstream effector proteins and it is still unclear
whether targeting the kinase itself or its regulators/
modulators will provide the most pronounced anti-
neoplastic effect.
In our previous investigations, we could confirm that
malignant tissues from patients with localized prostate
cancer are frequently characterized by increased expres-
sion of phospho-Akt (Ser473). Interestingly, only in a
subgroup of the patients increased expression of phos-
pho-Akt correlated with loss or inactivation of its
upstream regulator PTEN [8]. Moreover, we found a
substantial heterogeneity in the expression and phos-
phorylation levels of the Akt-downstream targets fork-
head transcription factor like 1 (FKHRL1), glycogen
synthase kinase-3b (GSK3b), and mammalian target of
rapamycin (mTOR). Thus, the existence of different
molecular subgroups with distinct sensitivity to small
molecule inhibitors of the PI3K/Akt-pathway and radio-
therapy can be assumed [8].
Alkylphosphocholines are lysophospholipid-like inhibi-
tors of the signal transduction pathways with anti-neo-
plastic properties. In contrast to classic genotoxic
chemotherapy and radiotherapy, these lipophilic drugs
target cellular membranes and interfere with membrane
lipid composition and the formation of lipid second
messengers, thereby affecting the growth, cell cycle pro-
gression, and survival of tumor cells without any direct
effects on the genome [9]. The use of two clinically rele-
vant derivatives, the oral drug perifosine and the proto-
typic intravenously applicable ErPC3, in preclinical and
clinical investigations is based on their ability to induce
apoptosis in tumor cells and their ability to increase
cytotoxic efficacy of chemotherapy and radiotherapy in
preclinical investigations [10-12]. Induction of apoptosis
by ErPC3 and related drugs occurs mainly via the mito-
chondrial pathway which is controlled by several pro-
and anti-apoptotic members of the Bcl-2 protein family
[13,14]. However, particularly in leukemic cells, the
extrinsic pathway can also be involved [15]. The cyto-
toxic action of synthetic phospholipid analogs relies on
their ability to affect specific signaling processes in the
tumor cells such as the proapoptotic stress-activated
protein kinase (SAPK)/c-jun-NH2-terminal kinase (JNK)
pathway, the prosurvival PI3K/Akt pathway, and the
mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK) pathway [9].
Here we evaluated of the anti-neoplastic activity of the
putative Akt inhibitor ErPC3 in different prostate cancer
cell lines in vitro. ErPC3´s anti-neoplastic action was
compared to that of the known PI3K-inhibitor
LY294002. In addition, we compared the anti-neoplastic




ErPC3 was synthesized by H. Eibl, Max Planck Institute
of Biophysical Chemistry, (Goettingen, Germany) and
d i s s o l v e di nR P M I1 6 4 0m e d i u ma t1 0m g / m l .
LY294002 was obtained from Cell Signaling (Frankfurt,
Germany). Rabbit antibodies against PARP, caspase-3,
Akt, phospho-Akt (Ser473), Bax, Mcl-1, and Bcl-xL
were purchased from Cell Signaling (Frankfurt, Ger-
many), the rabbit anti-Bak NT antibody was from
Upstate (Biomol, Hamburg, Germany). Mouse anti-
ß-Actin was obtained from Sigma-Aldrich (Deisenhofen,
Germany). HRP-conjugated anti-rabbit and anti-mouse
secondary antibodies were from Amersham-Biosciences
(Freiburg, Germany). All other chemicals were pur-
chased from Sigma-Aldrich (Deisenhofen, Germany) if
not otherwise specified.
Cell lines and cell culture
The prostate cancer cell lines LNCaP (p53 wild type,
androgen-dependent, highly differentiated), PC3 (p53-/-,
androgen-independent, poorly differentiated), and
DU145 (p53 mutant, androgen-independent, moderately
differentiated) were obtained from ATCC (Bethesda,
Maryland, USA). For all experiments cells were grown
in RPMI 1640 medium supplemented with 10% (v/v)
fetal calf serum (Gibco Life Technologies, Eggenstein,
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37°C and 5% CO2.
Treatment of cells
Cells were irradiated at room temperature with 6 MV
photons from a linear accelerator (LINAC SL25 Phillips)
at a dose rate of 4 Gy/min at room temperature. A sin-
gle dose of 2 Gy, 5 Gy, or 10 Gy was applied. ErPC3
was used at a final concentration of 1-100 µM, the PI3K
inhibitor LY294002 was used at a final concentration of
25-100 µM.
Cell proliferation and viability assay
10
3,2×1 0
3 or 3 × 10
3 cells/well were seeded in 96 well
plates and left to attach at 37°C over night. Subse-
quently, cells were stimulated as described above. Cell
survival was measured at indicated time points by add-
ing 10 µl of a 1:3 (v/v) diluted ready to use WST-1 cell
proliferation reagent stock solution (Roche, Mannheim).
Samples were incubated for 60-240 min and absorption
was measured with ANTHOS® MTP reader (Anthos
Mikrosystheme GmbH, Krefeld, Germany) at 450 nm
wavelength using a 620 nm reference filter. After sub-
traction of the background absorption, the mean values
of the untreated control cells were set as 100%.
DNA fragmentation
Nuclear fragmentation was determined after staining the
cells with 5 µg/mL propidium iodide in a hypotonic buf-
fer containing 0.1% sodium citrate and 0.1% Triton
X-100 for 1 h at room temperature. The stained cells
were detected in channel 2 employing a FACS Calibur
flow cytometer and the Cell Quest software (Becton
Dickinson, Heidelberg, Germany). Flow cytometric ana-
lysis was performed using FCS Express software
(De Novo Software, Los Angeles, CA, USA).
Western blot
Cells were lysed in lysis buffer containing 50 mM
HEPES pH7.5, 150 mM NaCl 1% Triton X-100, 1 mM
EDTA, 10 mM sodium pyrophosphate, 10 mM NaF,
2m MN a 3VO4,1 0 0m MP M S F ,5µ g / m lA p r o t i n i n ,
5 µg/ml Leupeptin, and 3 µg/ml Pepstatin. After remov-
ing insoluble material by centrifugation for 10 min at
13 000 r.p.m., the protein concentration was estimated
in the supernatant using the Bio-Rad protein assay (Bio-
Rad, Munich, Germany) according to the manufacturer’s
protocol. Lysates were separated by SDS-PAGE under
reducing conditions before transfer onto PVDF-
membranes (Roth, Karlsruhe, Germany). Equal protein
loading was confirmed by Ponceau S staining. Blots
were blocked in TBS buffer containing 0.05% Tween 20
and 5% non-fat dried milk for 1 h at room temperature.
The membrane was incubated over night at 4°C with
the respective primary antibodies. After repeated wash-
ings with TBS/Tween-20 (0.05%) the membranes were
incubated with the secondary antibody for 1 h at room
temperature before repeating the washing with TBS/
Tween-20 (0,05%). Detection of antibody binding was
performed by enhanced chemoluminescence according
to the manufacturer’s protocol (ECL Western blotting
analysis system, GE Healthcare/Amersham-Biosciences,
Freiburg, Germany).
Data analysis
Experiments were at least performed in triplicate. Data
were represented as means ± SD (DNA fragmentation
and cell proliferation/viability assay) or as one represen-
tative out of three similar experiments (Western Blot).
Statistical significance was calculated by ANOVA test
using GraphPad Software (San Diego, CA, USA, http://
www.graphpad.com).
Results
Antineoplastic efficacy of ionizing radiation and ErPC3 in
prostate cancer cell lines
In a first step, the anti-neoplastic effects of ErPC3 and
ionizing radiation alone were analyzed in three different
prostate cell lines. For this, PC3, DU145, and LNCaP
cells were subjected to single doses of ionizing radiation
between 2 Gy and 10 Gy or treated with different con-
centrations of ErPC3 (1 µM to 100 µM). 48 h later, cells
were subjected to the WST-1 proliferation/viability
assay. In LNCaP cells, ionizing radiation reduced the
number of viable cells already at low doses (Figure 1C).
In contrast, PC3 and DU145 cells remained almost
unaffected by radiation treatment, even when higher
radiation doses (5 or 10 Gy) were applied (Figure 1A
and Figure 1B). Interestingly, PC3 cells were highly sen-
sitive to treatment with ErPC3: we observed a 50%
r e d u c t i o ni nt h en u m b e ro fviable cells already upon
treatment with 25 µM ErPC3 (Figure 1D). However, the
same drug concentration failed to reduce the number
of viable DU145 and LNCaP cells (Figure 1E and
Figure 1F). Both cell types were only affected by treat-
ment with ErPC3 when concentrations of 50 µM ErPC3
or higher were used.
Apoptosis-induction by ErPC3 and ionizing radiation in
prostate cancer cell lines
The WST-1 assay mirrors just the number of viable cells
a tas p e c i f i ct i m ep o i n t ,b u td o e sn o ti n d i c a t ew h e t h e r
the therapy effects observed are due to inhibition of pro-
liferation, cell death induction, or both. Therefore, in a
next step, we examined whether the anti-neoplastic
effects of ErPC3 and ionizing radiation include induc-
tion of cell death, in particular apoptosis. These investi-
gations were performed in the highly ErPC3-sensitive
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using flow cytometric detection of apoptosis-related
nuclear fragmentation (Figure 2). As shown in Figure
2A, ErPC3 induced prominent DNA fragmentation in
PC3 cells already at low dose treatment (5 µg/mL
ErPC3). In contrast, 25 µM ErPC3 were needed to
trigger a significant amount of cells with nuclear frag-
mentation in LNCaP cells (Figure 2B). So far, these
observations were in line with the data obtained from
the WST-1 viability assay. As expected from the results
of the WST-1 assay, we hardly detected any apoptosis in
PC3 cells in response to ionizing radiation (Figure 2C).
However, despite reducing the number of viable cells in
the WST-1 assay, ionizing radiation did not induce sig-
nificant apoptotic nuclear fragmentation in LNCaP cells
( F i g u r e2 D ) .I nl i n ew i t ht h e s ef i n d i n g s ,c a s p a s e - 3
activation - as indicated by p19 and p17 cleavage pro-
ducts - and cleavage of the caspase-3 substrate Poly-
(ADP-ribose)-Polymerase (PARP) was only observed in
the lysates of ErPC3-treated prostate cancer cells but
not in the lysates of irradiated prostate cancer cells (Figure
3A and Figure 3B). These results indicated that ErPC3 is
able to trigger apoptosis in PC3 and LNCaP prostate can-
cer cell lines, although with different potency. In contrast,
the anti-neoplastic effects of ionizing radiation in LNCaP
cells did not involve apoptosis induction implicating a role
of proliferation inhibition or the induction of non-apopto-
tic or delayed cell death modes.
Impact of ErPC3 and ionizing radiation on the levels of
Bcl-2 proteins
A ss h o w ni np r e v i o u si n v e s t i g a t i o n s ,E r P C 3i n d u c e s
apoptosis via the intrinsic mitochondrial pathway [16].
We therefore next examined whether the differences in
apoptosis sensitivity of LNCaP and PC3 cells may be
related to differences in the basal levels or treatment-
induced changes in the expression of several proteins
of the Bcl-2 family known to function as key regulators
of the mitochondrial homeostasis and intrinsic apopto-
sis. As shown in Figs. 3C and 3D, PC3 and LNCaP
Figure 1 Anti-neoplastic effects of ErPC3 and ionizing radiation on prostate cancer cells. The prostate cancer cell lines PC3, DU145, and
LNCaP, were irradiated (RT) with 2, 5, or 10 Gy (A-C) or treated with 1-100 µM ErPC3, as indicated (D-F). 48 h after treatment a WST-1 Assay was
performed. The absorption correlates with the number of viable cells and was normalized to that of untreated controls. PC3 (A) and DU145 (B)
were not affected by ionising radiation whereas the number of viable LNCaP cells was reduced 48 h after irradiation (C). All cell lines responded
to ErPC3-treatment in a concentration-dependent manner. The androgen-independent cell line PC3 was most sensitive to ErPC3 (D). 25 µM
ErPC3 reduce the number of viable PC3 cells by approximately 50% whereas 50 µM ErPC3 were needed to affect the viability of DU145 (E) and
PC3 cells (F).
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expression levels of those pro-apoptotic effector pro-
teins were not affected by treatment with ErPC3 or
ionizing radiation. LNCaP and PC3 cells expressed the
anti-apoptotic Bcl-2 proteins Bcl-xL, Mcl-1, and Bcl-2,
although at different levels: Both cell lines expressed a
high amount of Bcl-xL, and an intermediate amount of
Mcl-1, whereas expression levels of Bcl-2 were inter-
mediate (LNCaP-cells) or low (PC3-cells) (Figure 3C
and 3D). Treatment with ErPC3 did not affect the pro-
tein levels of Bcl-xL and Bcl-2 in LNCaP and PC3
cells, whereas ionizing radiation triggered a decrease in
the levels of Bcl-2 in both cell lines. Moreover, ErPC3-
treatment decreased the levels of Mcl-1 in LNCaP
cells. Thus, in LNCaP cells the down-regulation of the
two anti-apoptotic Bcl-2 proteins may contribute to
the antineoplastic effects of ErPC3 and radiotherapy.
In contrast, the radiation-induced down-modulation of
t h ev e r yl o wB c l - 2 - l e v e l sm a yb eo fm i n o ri m p o r t a n c e
for the regulation of cell survival in PC3 cells. The dif-
ferential effect on Mcl-1 expression does not provide a
molecular basis for the distinct sensitivities of PC3 and
LNCaP cells to ErPC3-treatment since the levels of
Mcl-1 remained unaffected in the highly ErPC3-sensi-
tive PC3 cells.
Impact of ErPC3 on the phosphorylation state of protein
kinase B (Akt)
The apoptosis threshold of tumor cells is controlled by
various survival pathways including the PI3K/Akt path-
way. This pathway is frequently deregulated in prostate
cancer patients. It has been shown earlier that the anti-
neoplastic action of ErPC3 and related compounds is
associated with the inhibition of Akt [14,17,18]. We
therefore next evaluated the potential of ErPC3 to inhi-
bit the survival kinase Akt in PC3 and LNCaP prostate
cancer cells. Moreover, we compared the effects of
ErPC3 to the effects of the PI3K inhibitor LY294002.
LY294002 inhibits the upstream kinase PI3K thereby
preventing the activation of Akt. PC3, LNCaP, and
DU145 cells were treated with 25-100 µM ErPC3 or
LY294002 for 48 h before analyzing the number of
viable cells by the WST-1 assay (Figure 4). As already
depicted in Figure 1A, PC3 cells were most sensitive to
the treatment with ErPC3. In these cells treatment with
25 µM ErPC3 was sufficient to reduce the number of
Figure 2 Apoptosis induction in response to ErPC3 and ionizing radiation. PC3 and LNCaP cells were treated with 1-50 µM ErPC3 or
irradiated with a single dose of 2 or 10 Gy. 48 h later, cells were stained with propidium iodide in a hypotonic citrate buffer containing Triton X-
100 and subjected to flow cytometric analysis to estimate DNA fragmentation which occurs upon induction of apoptosis. 5 µM ErPC3 were
sufficient to induce DNA fragmentation in PC3 cells (A), whereas 25 µM ErPC3 were required to trigger apoptotic DNA-fragmentation in LNCaP
cells (B). Ionizing radiation up to 10 Gy did not induce DNA-fragmentation above a background level in PC3 (C) and LNCaP cells (D).
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100 µM ErPC3 were required to obtain a similar
response in LNCaP and DU145 cells, respectively
(Figure 4A, left panel). The observed differences of the
relative absorption in this experiment as compared to
that in Figure 1 are due to slightly different experimen-
tal procedures. Higher cell numbers and longer incuba-
tion time with WST-1 resulted in an increased absolute
absorption and smaller error bars. A completely
different picture was obtained when testing the anti-
neoplastic potency of the PI3K inhibitor LY294002 (Fig-
ure 4B, left panel). In these investigations, LNCaP cells
turned out to be the most sensitive of the three prostate
cancer cell lines. 25 µM LY294002 reduced the number
of viable LNCaP cells by more than 50% whereas 100
µM LY294002 were required to exhibit a similar inhibi-
tory potential in PC3 cells. Again, DU145 cells displayed
only very modest sensitivity to the inhibition of the
PI3K/Akt pathway (Figure 4B, left panel).
The differences in the sensitivity may be due to a dis-
tinct potential of the drugs to interfere with Akt signal-
ing. We therefore next examined treatment-induced
changes in the levels of phospho-serine 473 Akt (p-Akt).
Phosphorylation at serine 473 is required to obtain full
Figure 3 Activation of caspase-3 and regulation of Bcl-2 protein family members in response to ErPC3-treatment and irradiation. PC3
and LNCaP cells were treated with 0-25 µM ErPC3 or irradiated with 2 or 10 Gy. Cells lysates were generated 48 h after treatment, separated by
electrophoresis, and protein expression was subsequently analyzed by western blotting. Both cells lines showed a concentration-dependent
activation of caspase-3 in response to ErPC3-treatment (A, B). In PC3 cells, cleavage of the caspase-3 substrate PARP could already be detected
after treatment with 12.5 µM ErPC3; PARP-cleavage was accompanied by a weak activation of caspase-3 detectable upon treatment with 12.5
µM ErPC3 (A). A weak cleavage of caspase-3 and PARP was also observed when LNCaP cells were treated with 12.5 µM ErPC3, but cleavage was
clearly visible after treatment with 25 µM ErPC3 (B). No caspase-3 activation and PARP cleavage was observed in response to ionizing radiation.
No change of protein levels of the pro-apoptotic Bak and Bax and the anti-apoptotic Bcl-xL was observed upon irradiation or in response to
treatment with ErPC3 (C, D). A slight reduction in the levels of antiapoptotic Bcl-2 was observed upon irradiation in LNCaP and PC3 cells,
whereas treatment with ErPC3 reduced the levels of the anti-apoptotic Mcl-1 in LNCaP cells. However, the changes of Mcl-1 expression levels
did not correlate with the sensitivity of LNCaP cells to ErPC3.
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treatment with ErPC3 caused a dramatic reduction in
the levels of p-Akt in PC3 cells. A less pronounced but
still remarkable reduction in p-Akt was observed in
LNCaP correlating with the different sensitivity of the
two cell lines to ErPC3. The PI3K inhibitor LY294002
(50µM) largely reduced p-Akt-levels in LNCaP cells.
Maximal inhibition was already observed 1 h after addi-
tion of LY294002 to LNCaP cells, but p-Akt was still
reduced 2 days later (Figure 4B right panel). Interest-
ingly, in PC3 cells treatment with LY294002 was with-
out effect on the phosphorylation state of Akt. Even 48
h after treatment, p-Akt levels remained unaffected (Fig-
ure 4B right panel). Because PC3 cells were highly resis-
tant to the treatment with LY294002, these observations
suggest that a down-regulation of p-Akt may be
required for the anti-neoplastic action of small molecule
inhibitors of the PI3K/Akt pathway in prostate cancer
cells.
Combined effects of ErPC3 and ionizing radiation in
prostate cancer cell lines
Up to now our data revealed that ErPC3 is a potent
inhibitor of Akt even in cells that are highly refractory
to inhibitors acting upstream of Akt in the same path-
way. Because inhibition of Akt can lower the threshold
for cell death induction, we next examined whether an
inhibition of the Akt survival pathway by ErPC3
sensitizes the cells to the cytotoxic effects of ionizing
radiation. Cells were exposed to different ErPC3 concen-
trations in combination with 0, 2, 5, or 10 Gy. 48 h later
the number of viable cells was determined using the
WST-1 assay (Figure 5). While treatment with ionizing
radiation was without effect, treatment with ErPC3
Figure 4 Differential effects of ErPC3 and LY294002 on prostate cancer cell survival and p-Akt levels. (A, B, left panels) DU145, LNCaP,
and PC3 cells were treated with solvent controls or 25-100 µM ErPC3 or 25-100 µM LY294002. 48 h later a WST-1 assay was performed to
quantify the number of viable cells. PC3 cells were most sensitive to treatment with ErPC3 (A, left panel), whereas LNCaP cell were most
susceptible to LY294002-treatment (B, left panel). Western blot analysis of lysates generated from PC3 cells 48 h after treatment with 0-25 µM
ErPC3 showed a massive reduction of Akt-phosphorylation at serine 473 (p-Akt) whereas almost no reduction of p-Akt was found 48 h after
irradiation with 2 or 10 Gy (A, right panel). ErPC3 also reduced p-Akt levels in LNCaP cells however with lower potency (A, right panel). Western
blot analysis of lysates generated 0-48 h after treatment with 50 µM LY294002 showed a massive down-modulation of p-Akt-levels in LNCaP
cells within 1 h after treatment; still, a considerable reduction in p-Akt levels could be detected 48 h after treatment. In contrast, LY294002 failed
to reduce p-Akt levels in PC3 cells at any time point measured (B, right panel).
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number of viable PC3 and DU145 cells. Additional irra-
diation of the cells did not significantly enhance the
anti-neoplastic effects compared to single treatment
with ErPC3 (Figure 5A and Figure 5B). In LNCaP cells,
irradiation with 2 to 10 Gy or treatment with 50 to
100 µM ErPC3 led to a prominent reduction in the
number of viable LNCaP cells. When irradiation was
combined with subtoxic concentrations of ErPC3, the
anti-neoplastic effects of the combined treatment were
mainly due to the effects of ionizing radiation (Figure
5C). Only when using a toxic concentration of ErPC3
(50µM), the combination of drug treatment and ionizing
radiation was able to further increase the anti-neoplastic
effects compared to single treatment with ErPC3 or irra-
diation alone. As already mentioned above, the Wst-1
test is suited to determine the number of viable cells
but does not provide information about the contribution
of cytostatic or cytotoxic effects of the treatment under
investigation. Therefore, to gain insight into a combina-
tion effect on apoptosis induction we subsequently
assessed DNA-fragmentation by using flow cytometry
and caspase-activation by using Western blot analysis.
In PC3 cells treatment with 12.5 µM ErPC3 alone effec-
tively induced apoptosis whereas irradiation alone was
almost without effect. The combination of 12.5 µM
ErPC3 and 10 Gy led to a small but significant increase
in the apoptosis rate compared to either treatment
alone (Figure 6A). In LNCaP cells, combined treatment
with 12.5 µM ErPC3 and ionizing radiation (10 Gy)
induced significant apoptosis although, when applied
alone, neither irradiation nor ErPC3 induced apoptotic
DNA-fragmentation (Figure 6B). The increased pro-
apoptotic effects of ionizing radiation in combination
with ErPC3 were also detected when analyzing apoptosis
signaling by Western blotting: In both cell types, activa-
tion of caspase-3 was increased upon combined treat-
ment compared to either treatment alone (Figure 6C
and 6D).
Taken together, our results show that the Akt-inhibitor
ErPC3 increases radiation-induced apoptosis in prostate
cancer cells. The most prominent combination effects
were obtained in LNCaP cells that did not show
any apoptosis in response to treatment with irradiation
alone.
Discussion
Although improved screening methods allow a diagnosis
of prostate cancer at an early stage, it still remains one
major cause of death in men in industrialized countries.
In particular, no curative treatment is available to date
upon progression to androgen-independent and meta-
static disease. Therefore, current research focuses on
signal transduction inhibitors to improve the treatment
outcome. Based on its suggested role in tumor progres-
sion and resistance to standard chemotherapy and
radiotherapy, the PI3K/Akt pathway constitutes an
attractive therapeutic target in prostate cancer [8,19,20].
Many pharmaceutical companies hunt for novel drugs
that interact with the Akt pathway [7]. A group of these,
the synthetic phospholipid derivatives perifosine and
erucylphosphohomocholine (ErPC3) constitute interest-
ing compounds as they affect intracellular signaling cas-
cades upon primary interaction with cellular membranes
Figure 5 Anti-neoplastic effect of combined treatment with ErPC3 and ionizing radiation. PC3 cells (A), DU145 cells (B), and LNCaP cells
(C) were treated with increasing concentrations of ErPC3 (1-100 µM) and ionizing radiation (2, 5, 10 Gy) alone or in combination as indicated.
Cell viability was analyzed 48 h after treatment by using the WST-1 assay. PC3 and DU145 cell did not respond to irradiation alone but
responded to single treatment with ErPC3 (A, B). The anti-neoplastic effects of the combination were mainly attributed to the effects of ErPC3 (A,
B). In contrast, LNCaP cells were highly sensitive to treatment with radiation alone, as well as to ≥ 50 µM ErPC3 (C). When LNCaP cells were
treated with subtoxic ErPC3-concentrations in combination with irradiation, the reduction in the number of viable cells was mainly due to
ionizing radiation (C). However, the cell viability was further reduced when LNCaP cells were treated with toxic ErPC3-concentrations (≥ 50µM) in
combination with irradiation.
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no major side effects [21]. Here, we show for the first
time that the paradigmatic intravenously applicable
alkylphosphocholine ErPC3 potently induces apoptosis
in prostate cancer cells in vitro. These findings corrobo-
rate earlier reports on high efficacy of ErPC3 in human
glioblastoma, lymphoma, leukemia, and breast cancer
cells in vitro [10,14,22-25]. Notably, the hormone-inde-
pendent cell line PC3 was even more sensitive to the
cytotoxic effects of ErPC3 than the hormone-responsive
cell line LNCaP. In both cell lines, the cytotoxic efficacy
of ErPC3 was associated with a reduction in the cellular
levels of phospho-Serine 473 Akt (p-Akt) which is indi-
cative for the activation state of this survival kinase.
Again, the dephopshorylation of Akt by ErPC3 was
more prominent in the highly ErPC3-sensitive PC3 cells
compared to the less responsive LNCaP cells. A potent
p-Akt-inhibitory action of ErPC3 in association with
prominent cytotoxic drug activity was also observed in
human malignant glioma cell lines in our earlier investi-
gations [12,14,25]. Similarly, malignant glioma cells are
also mostly characterized by an increased activation of
the PI3K/Akt survival pathway. Our data also corrobo-
rate earlier reports about potent Akt-inhibition by the
orally available alkylphosphocholine perifosine in differ-
ent solid tumor cells in vitro including lung and prostate
cancer [12,14,17,25,26]. Altogether, these observations
suggest a role of Akt-inhibition for the cytotoxic actions
of ErPC3 and related compounds when used as single
drugs. However, it cannot be excluded that additional
effects of ErPC3 and related compounds may contribute
to their antineoplastic effects. Here, among others the
pro-apoptotic SAPK/JNK pathway, the MAPK/ERK
pathway, the sphingolipid pathway, the cell cycle con-
trolling retinoblastoma protein, the F(0)F (1)-ATP
synthase, and protein phosphatase 2A have been
described as important drug targets [9,27-29].
Interestingly, the anti-neoplastic activity of the PI3K
inhibitor LY294002 on the prostate cancer cells differed
considerably from the effects of ErPC3: LY294002
exerted its strongest anti-neoplastic effects in LNCaP
cells whereas the highly ErPC3-sensitive PC3 cells
Figure 6 Combined effects of ErPC3 and ionizing radiation on apoptosis induction in prostate cancer cell lines. PC3 and LNCaP cells
were irradiated with 10 Gy, treated with 12.5 µM ErPC3 or both treatments were combined. DNA fragmentation (A, B) and caspase activation (C,
D) were analyzed 48 h later. (A) Approximately 30% of PC3 cells showed DNA fragmentation after a single treatment with ErPC3, whereas
radiation-induced apoptosis was below 10%. The amount of apoptotic cells significantly increased when cells were subjected to combined
treatment (data show means ± SD; n = 3; ***: p < 0,001). (B) Although a single therapy with ionizing radiation or ErPC3 did not induce
apoptotic DNA fragmentation in LNCaP cells, the combination of both treatments resulted in apoptosis levels comparable to that in PC3 cells.
The results were confirmed by Western blotting analyzing caspase-3 and PARP cleavage (C, D). Cleavage of caspase-3 (PC3 and LNCaP cells) and
PARP (LNCaP cells) was more effective when ErPC3 and ionizing radiation were combined (C, D).
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Importantly, LY294002-treatment reduced the phos-
phorylation of Akt only in the LY294002-sensitive
LNCaP cells but not in PC3 cells with low sensitivity to
LY294002. Thus, the antineoplastic activity of ErPC3
and LY294002 in prostate cancer cells correlated with
their potency to reduce p-Akt levels. Because ErPC3 and
LY294002 act at two distinct levels of the PI3K/Akt-
pathway to reduce Akt-activity, the distinct potency of
ErPC3 and LY294002 to inhibit Akt-activity in PC3 and
LNCaP cells suggests that two distinct but functionally
equivalent molecular changes promote up-regulated
activity of Akt in LNCaP and PC3 cells. This is reminis-
cent of our recent observation in tissue probes of
patients with localized prostate cancer: In the patients
tissues, up-regulated activity of Akt occured as a conse-
quence of PTEN-loss, PTEN-inactivation, or by PTEN-
independent mechanisms [8]. These observations may at
least partially explain the finding that the ErPC3-related
drug perifosine was only active in a subgroup of patients
with recurrent androgen-sensitive tumors [30].
In this regard, the PI3K-mediated formation of phos-
patidylinositol-3,4,5-triphophate (PIP3) plays a major
role in growth factor mediated activation of Akt. This
process is counteracted by the action of the tumor sup-
pressor PTEN which is lost or inactivated in a variety of
solid human tumors, including prostate cancer.
Increased levels of PIP3 trigger the recruitment of phos-
phatidylinositide-dependent serine/threonine kinase 1
(PDK1) and Akt to the cytoplasmic membrane where
PDK1 phosphorylates Akt on threonine 308. An addi-
tional phosphorylation on serine 473 is required to
fully activate Akt. Phosphorylation on threonine 308
obviously precedes phosphorylation on serine 473 but
phosphorylation on serine 473 seems to be independent
of PDK1. Although several kinases, such as integrin-
linked kinase, DNA-dependent protein kinase (DNA-
PK), and the mTOR/Rictor-complex have been pro-
posed to function as so-called “PDK-2” [31-34], the
identity of the serine-473 kinase is still controversial
[35]. There is accumulated evidence that LY294002
interferes with the activation of Akt by inhibiting its
upstream regulator PI3K. In contrast, membrane-tar-
geted alkylphosphocholines like ErPC3 interfere with
membrane composition thereby affecting the recruit-
ment of Akt to the plasma membrane which is a prere-
quisite for its activation by PDK1 [17]. On the basis of
this mechanism of action, ErPC3 and related com-
pounds would even be effective in cells where the high
activity of Akt is caused by a constitutively active PI3K
that is not inhibited by LY294002.
In our hands, treatment with LY294002 resulted in a
rapid and consistent downregulation of p-Akt levels in
the highly LY294002-sensitive LNCaP cells. ErPC3-
treatment also reduced p-Akt levels in LNCaP cells to a
substantial amount. The decrease in p-Akt was accom-
panied by the induction of cell death by both com-
pounds. This suggests that in LNCaP cells the
constitutive activation of the survival kinase Akt occurs
downstream of an overactive PI3K that is inhibited by
both, the PI3K inhibitor LY294002 and the Akt-inhibitor
ErPC3. In PC3 cells howerver, only ErPC3 reduced
p-Akt and induced cell death to a significant amount
when concentrations below 50 µM were used. This sug-
gests that the high p-Akt-levels in PC3 cells rely on a
LY294002-insensitive but ErPC3-sensitive mechanism.
Thus, PC3 cells may express a mutant PI3K that is
insensitive to inhibition by LY294002. Alternatively,
Akt-activation in PC3 cells may occur independently
from PI3K, e.g. by aberrant activation of Akt-activating
kinases or by loss or inactivation of p-Akt phosphatases.
There is accumulated evidence that constitutive acti-
vation of the PI3K/Akt pathway interferes with the cyto-
toxic action of ionizing radiation. On the other hand, it
is known from earlier investigations that the antineo-
plastic efficacy of ErPC3 is increased in human tumor
cells when the drug is combined with genotoxic agents
like cytarabine, idarubicine or etoposide, or with ioniz-
ing radiation, respectively [10,23]. Therefore, in a final
set of in vitro experiments, we analyzed whether treat-
ment with the Akt-inhibitor ErPC3 would increase the
short-time antineoplastic effects of ionizing radiation in
the prostate cancer cell lines. Combined treatment with
ErPC3 and 2, 5 or 10 Gy reduced the number of viable
LNCaP, PC3 and DU145 cells as determined by the
WST-1 test.
In PC3 and DU145 cells the antineoplastic effects of
the combination treatment cou l dm a i n l yb ea t t r i b u t e d
to the concentration-dependent effects of ErPC3.
Although in the WST-1 assay additional irradiation did
not cause a further decrease in viable DU145 or PC3
cells, a small but significant increase in the amount of
apoptotic PC3 cells could be detected by flow cytometry
when ErPC3-treatment was combined with ionizing
radiation compared to ErPC3 treatment alone. The dis-
crepancies between the results from the WST-1 test and
flow cytometry may be due to the high standard devia-
tions in the WST-1 test that would preclude the detec-
tion of a small combination effect. On the other hand,
in cell culture apoptotic cells remain viable at the early
stages and die from late apoptosis/necrosis. Thus, early
apoptotic cells may be detected as viable in the Wst-1
test, thereby leading to an underestimation of an
apoptosis-based cytotoxic drug effect.
In LNCaP cells, the major part of the combination
effects seemed to be based on the radiation effects at
least when non-toxic concentrations of ErPC3 were
used. However, when combining a cytotoxic ErPC3
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prominent reduction in the number of viable cells was
achieved compared to either treatment alone. These
results were corroborated by the apoptosis determina-
tions: Although LNCaP cells were resistant to apoptosis
induction by single treatment with ionizing radiation or
low concentrations of ErPC3, a pronounced increase of
apoptotic cell death was already observed when combin-
ing 12.5 µM ErPC3 and ionizing radiation. The radia-
tion-induced down-regulation of Bcl-2 together with the
ErPC3-induced down-regulation of Mcl-1 and p-Akt
may be sufficient to overcome the cellular death thresh-
old and to induce apoptotic death of LNCaP cells
[16,36]. In PC3-cells, ionizing radiation also decreased
cellular Bcl-2 levels but ErPC3 did not reduce the levels
of anti-apoptotic Mcl-1. The rather low levels of Bcl-2
in the PC3 cells may explain why the radiation-induced
down-modulation of Bcl-2 was of minor importance for
the response of PC3-cells to radiotherapy and the
combined treatment.
Our novel data emphasize a potential therapeutic
benefit of the alkylphosphocholine ErPC3 when used as
single drug or in combination with ionizing radiation in
prostate cancer. Recent phase-I trials already demon-
strated feasibility and tolerability of an intravenous ther-
apy with ErPC3 for patients with advanced human
malignancies (personal communication of L. Lindner,
Department of Internal Medicine III, Universität
München-Großhadern, Germany). Also, the ErPC3-
related compound perifosine was well tolerated in clini-
cal trials and displayed clinical activity in hematological
malignancies and in a subgroup of patients with recur-
rent androgen-sensitive prostate cancer [11,30,37]. More-
over, in a recent phase-II-study a single treatment with
oral perifosine prolonged the progression free survival
and induced a minimal response in a group of patients
with Waldenstrom’s Macroglobulinema [37]. On the
basis of its potential efficacy in patients with recurrent
androgen-sensitive tumors, perifosine is currently being
developed as an oral Akt inhibitor for prostate cancer
[30]. It is expected that a combination therapy with other
anti-neoplastic agents or ionizing radiation will further
enhance these effects. The clinical use of this class of
neoplastic agents is of particular interest because, in con-
trast to standard genotoxic therapies and ionizing radia-
tion, these drugs target cellular membranes without a
direct interaction with the cellular DNA. Consequently,
these lipophilic drugs lack bone-marrow toxicity and
even exert growth stimulatory effects on hematopoietic
progenitor cells [38,39]. The lack of hematotoxicity, and
the improved solubility compared to perifosine make
ErPC3 the first intravenously applicable alkylphospho-
choline for the use in clinical trials allowing a faster drug
accumulation in the tumor tissue [40].
In summary, our data underline the relevance of Akt
as a therapeutic target in prostate cancer. However, it
has to be taken into account that Akt inhibitors with a
differential mechanism of action will have differential
effects in prostate tumors with a distinct genetic back-
ground. A detailed molecular profiling of the tumor
cells of each patient as well as the definition of biomar-
kers which predict the drug response will be of utmost
importance to choose the best drug for each patient.
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